Home / Business and Economy / AbbVie Stock Dips Despite Strong Revenue Growth
AbbVie Stock Dips Despite Strong Revenue Growth
1 Aug
Summary
- AbbVie's Q2 revenue rose over 10% year-over-year to $17 billion.
- Adjusted earnings per share missed analyst estimates, impacting stock.
- The company lowered its 2026 earnings guidance due to an acquisition.
AbbVie reported its second-quarter financial results, with revenue climbing over 10% from the previous year to just under $17 billion. The company also saw a significant 23% increase in adjusted net income, reaching nearly $6.5 billion, or $3.65 per share. Despite these positive growth figures, AbbVie's adjusted profitability did not meet the average analyst estimate of $3.71 per share, although it surpassed the consensus revenue projection of $16.77 billion.
The immunology division, AbbVie's largest, experienced a 15% global revenue increase to $8.79 billion, propelled by the success of Skyrizi. Neuroscience also showed strong performance with a 20% rise in revenue, totaling $3.2 billion. However, the oncology segment saw a slight decline of nearly 2%, bringing in $1.65 billion.
A key factor contributing to investor disappointment was AbbVie's revised earnings guidance for the full year 2026. The company now anticipates earnings between $13.87 and $14.07 per share, a slight reduction from its prior forecast of $13.91 to $14.11. This adjustment, influenced by the significant acquisition of Apogee Therapeutics, falls below the consensus analyst estimate of $14.12, leading to a stock sell-off on Friday.
